Immunotherapy with checkpoint inhibitors is standard for recurrent or metastatic HNSCC, but its efficacy in radioimmunotherapy is limited by low PD-1/PD-L1 expression and unpredictable clinical responses [59]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.